Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2005-08-30
2005-08-30
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S611000
Reexamination Certificate
active
06936639
ABSTRACT:
Administration of an HNO/NO−donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure Moreover, administration of the HNO/NO−donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO−donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO−donors, administration of an HNO/NO−donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent Further, HNO/NO−exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy
REFERENCES:
patent: 4954526 (1990-09-01), Keefer
patent: 5039705 (1991-08-01), Keefer et al.
patent: 5212204 (1993-05-01), Keefer et al.
patent: 6083515 (2000-07-01), Garvey et al.
patent: 6143734 (2000-11-01), Garvey et al.
patent: RE37116 (2001-03-01), Garvey et al.
patent: 6297260 (2001-10-01), Bandarage et al.
patent: 6323234 (2001-11-01), Garvey et al.
patent: 2002/0010146 (2002-01-01), Garvey et al.
patent: 2002/0016322 (2002-02-01), Bandarage et al.
patent: WO 96/32946 (1996-04-01), None
patent: WO 98/43621 (1998-03-01), None
patent: WO 99/33823 (1998-12-01), None
patent: WO 00/67754 (2000-05-01), None
patent: WO 01/45703 (2000-12-01), None
patent: WO 02/060378 (2001-12-01), None
Harrison's Principles of Internal Medicine, Isselbacher et al. eds., 13thed. vol. 1, 1994, pp 1002-1008.
Hart et al., Abstract,Am J Physiol Heart Circ Physiol, vol. 281, No. 1, pp. H146-H154 (Jul. 2001).
Paolocci et al., Abstract,Italian Heart Journal, vol. 2, Suppl. 3, p. 62S (Sep. 2001).
Paolocci et al.,PNAS, vol. 98, No. 18, pp. 10463-10468 (Aug. 28, 2001).
Pagliaro et al.,J. Physiol., vol. 536, p. 143P (2001).
Ma et al.,PNAS, vol. 96, No. 25, pp. 14617-14622 (1999).
Maragos et al.,J. Med. Chem., vol. 34, No. 11, pp. 3242-3247 (1991).
Fitzhugh et al.,Free Radical Biology&Medicine, vol. 28, No. 10, pp. 1463-1469 (2000).
Pagliaro et al., Abstract 1265,Supplement to Circulation, vol. 104, No. 17, pp. 11-263-11-264 (2001).
Feelisch Martin
Fukuto Jon
Kass David A.
Katori Tatsuo
Miranda Katrina
Henley III Raymond J.
Johns Hopkins University
Klarquist & Sparkman, LLP
The Board of Supervisors of Louisiana State University and Agric
The Regents of the University of California
LandOfFree
Nitroxyl progenitors in the treatment of heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitroxyl progenitors in the treatment of heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitroxyl progenitors in the treatment of heart failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3447756